Cancer immunotherapy in 2017

The breakthrough of the microbiota

In 2017, epidemiological studies in humans and experiments in mouse models showed that the intestinal microbiota determines the effectiveness of anticancer immunotherapies. As such the microbiota offers new prognostic biomarkers and shows promise as a target for future antineoplastic treatments.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Impact of bacteria on immuno-oncology.

References

  1. 1

    Geva-Zatorsky, N. et al. Mining the human gut microbiota for immunomodulatory organisms. Cell 168, 928–943 (2017).

    CAS  Article  PubMed  Google Scholar 

  2. 2

    Haber, A. L. et al. A single-cell survey of the small intestinal epithelium. Nature 551, 333–339 (2017).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. 3

    Bullman, S. et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 358, 1443–1448 (2017).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. 4

    Yu, T. et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 170, 548–563 (2017).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  5. 5

    Geller, L. T. et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 357, 1156–1160 (2017).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  6. 6

    Peled, J. U. et al. Intestinal microbiota and relapse after hematopoietic-cell transplantation. J. Clin. Oncol. 35, 1650–1659 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  7. 7

    Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018).

    CAS  Article  PubMed  Google Scholar 

  8. 8

    Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018).

    CAS  Article  PubMed  Google Scholar 

  9. 9

    Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104–108 (2018).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. 10

    Zitvogel, L. et al. Anticancer effects of the microbiome and its products. Nat. Rev. Microbiol. 15, 465–478 (2017).

    CAS  Article  PubMed  Google Scholar 

  11. 11

    Balachandran, V. P. et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 551, 512–516 (2017).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors are supported by grants from the Institut National contre le Cancer, Ligue Nationale contre le Cancer, Swiss Bridge Foundation, ISREC, RHU-TORINO-LUMIERE, SIRIC Socrates at Gustave Roussy and Seerave Foundation.

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Guido Kroemer or Laurence Zitvogel.

Ethics declarations

Competing interests

G.K and L.Z. are co-founders of everImmune, a biotech company that identifies bacteria for cancer treatment.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kroemer, G., Zitvogel, L. The breakthrough of the microbiota. Nat Rev Immunol 18, 87–88 (2018). https://doi.org/10.1038/nri.2018.4

Download citation

Further reading

Search

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing